Idorsia thanks Guy Braunstein for his years of service as he retires

• Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024

Allschwil, Switzerland – March 22, 2024
Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development and member of the Idorsia Executive Committee since the creation of Idorsia will retire at the end of March 2024. Guy will continue to support Idorsia as an advisor, especially in the analysis and interpretation of the data coming from the programs that he has initiated and led during his time with the company.

Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia commented:
“Over the last 15 years, Guy has made a huge contribution to Idorsia and to Actelion before that. As Head of Global Clinical Development until 2022, Guy was instrumental in successfully steering several drugs in several very different indications from rare diseases and specialty indications, such as pulmonary arterial hypertension, lysosomal disorders, and multiple sclerosis, to public health issues including insomnia and hypertension, through to approval. In his most recent role as Chief Medical Officer, Guy was critical in unifying the company’s quality and governance standards to ensure an uncompromisingly ethical and scientifically rigorous approach along the lifecycle of all products in Idorsia’s pipeline. I am very happy that we can continue to benefit from Guy’s vast experience after his retirement since he will serve as an advisor to Idorsia.”

Guy Braunstein, MD, PhD, and Chief Medical Officer of Idorsia commented:
“It has been an absolute privilege to work with an outstanding team of experts who are all dedicated to improving peoples’ lives with innovative medicines. I believe that bringing new drugs to prescribers and having a real impact on patients is one of the most rewarding endeavors. Having worked as a pulmonologist practitioner for a number of years, and joined the pharmaceutical industry in 1988, I am very proud of all that we have achieved over the past 15 years of my career at Actelion and Idorsia. I am satisfied that the clinical development is in safe hands with Alberto Gimona and, with the support of Antonio Olivieri, that we have all the correct checks and balances in place to ensure appropriate and safe use of Idorsia’s medicinal products and medical ethics in engagement with various stakeholders. I am therefore ready to hand the reigns over and start my retirement. I am also very happy to stay involved in the projects that have given me such job satisfaction over the years.”